We are looking forward to connecting with peers in the #oncology community at #ASCO25 as we share new data showing how our investigational #immunotherapy #pelareorep activates immune responses in #PancreaticCancer. Poster details here: bit.ly/42VdW53

New data from the GOBLET #ClinicalTrial presented with Arbeitsgemeinschaft Internistische Onkologie - AIO at #ASCO25 demonstrate how our investigational treatment #pelareorep, in combination with chemotherapy & a checkpoint inhibitor, activates immune responses in patients with #PDAC: bit.ly/4jdXDoL

We are headed to #BIO2025! Join our VP of Business Development, Christophe Degois, as he highlights how Oncolytics is partnering to transform #ImmunoOncology. Schedule a meeting with Christophe: bit.ly/3HvcMoF Biotechnology Innovation Organization

We shared new data from the GOBLET study in collaboration with Arbeitsgemeinschaft Internistische Onkologie - AIO at #ASCO2025 showing how our candidate, #pelareorep, in combo with chemotherapy and a checkpoint inhibitor, activates immune responses in #PancreaticCancer patients: bit.ly/42VdW53

Today we announced that Jared Kelly has been named CEO of Oncolytics. With expertise in biotech dealmaking and corporate strategy, his leadership will be critical as we advance #pelareorep as a potential new #immunotherapy for #cancer. Read more: bit.ly/4dTrrpG

This week, our CMO, Dr. Thomas Heineman, MD, PhD, will speak as part of Technology Networks’ virtual event on the advances in #immunooncology. Register here to learn how #pelareorep is driving progress in cancers by activating the immune system: bit.ly/4jHCgfY

This article by @LetsWinPC highlights #PancreaticCancer research that was presented at #ASCO25, including the new data we shared showing how our investigational therapy #pelareorep stimulates the immune system and primes tumors for treatment. Read more: bit.ly/3HZz95P

Andrew Aromando has joined Oncolytics as Chief Business Officer. He will lead global business development while contributing to corporate, clinical and regulatory strategies as we pursue aggressive clinical and business development initiatives. Read more: bit.ly/45P1qGm

Today we highlighted data from our completed clinical trials. Our investigational oncolytic virus immunotherapy, #pelareorep, showed strong survival benefits in pancreatic and breast cancers, supporting advancement to registration-enabling studies. More: bit.ly/44FKa44

On July 22 we will host a KOL event on the potential of our investigational #immunotherapy, #pelareorep, in pancreatic and gastrointestinal cancers. Experts will discuss our clinical data and how pelareorep fits into the treatment landscape. Register: bit.ly/4lNoDxk

Translational data for our investigational immunotherapy, #pelareorep, show viral replication and immune activation across multiple cancers. These findings reinforce its mechanism of action and potential as a platform therapy. Read our press release: bit.ly/3Iu9OBr

Thank you to the KOLs who joined our event to discuss the robust data supporting the clinical advancement of our investigational immunotherapy, #pelareorep, into registration-enabling studies. If you missed the live event, watch the replay here: bit.ly/452cFsG

This recent Targeted Oncology feature highlights survival data for our investigational immunotherapy #pelareorep and its potential in hard-to-treat cancers. The data support advancement of pelareorep into registration-enabling studies. Read the full article: bit.ly/4m3wQgQ

We have initiated regulatory discussions with the U.S. FDA for a registration-enabled pivotal study in first-line metastatic pancreatic ductal adenocarcinoma. Read more in our press release: bit.ly/44QXzrh #PancreaticCancer #PDAC #CancerResearch $ONCY

On Friday, August 8, at 10 a.m. ET, we will hold our virtual-only AGM for shareholders. Following the meeting, our CEO, Jared Kelly, will provide a corporate update. Our Q2 2025 financial results will also be reported that morning. Learn more: bit.ly/4m5ln0O $ONCY

Today we held our AGM, reported Q2 2025 financial results, reiterated our plan to pursue a registration-enabling study in first-line mPDAC and committed to limiting dilutive financings by terminating our ATM and ELOC. Read more: bit.ly/4mCpx03 $ONCY

In September, our CEO, Jared Kelly, will meet with institutional investors at the H.C. Wainwright 27th Annual Global Investment Conference and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference. Details here: bit.ly/4n8LeFk $ONCY

Today, we shared updated clinical safety data which demonstrate the consistent safety profile and potential of our investigational double-stranded RNA immunotherapy, #pelareorep, as a platform for treating gastrointestinal cancers. Read more: bit.ly/462vdtt

Today we highlighted data for our investigational double-stranded RNA #immunotherapy, #pelareorep in #ColorectalCancer, including KRAS mutants. Our studies show consistent efficacy, immune activation, and survival exceeding historical benchmarks: bit.ly/4pcw0Rn $ONCY

Today we shared progress updates for GOBLET, the trial for our investigational treatment, #pelareorep, in GI cancers with funding from PanCAN. ➡️ Cohort 4 data updates: Q4 2025 ➡️ Cohort 5 data updates: Q1 2026 ➡️ Expansion to the U.S. Details: bit.ly/3VfGNMZ